Financial Disclosure

Global M&A Value Up 15% as Megadeals Hit Record 37 in 2026

Boston – September 21, 2026 -- Global M&A value climbed 15% year over year in the first eight months of 2026, exceeding the ten-year average by 11%, according to a new report from Boston Consulting Group (BCG). The number of megadeals worth $10 billion or more rose to 37 from 24 a year earlier, surpassing 2021's record of 32.

Megadeal surge masks a narrower recovery below the top of the market

Transactions valued at $1 billion or more are running above longer-term norms, but deal volume for small-cap and midcap transactions remains below historical levels even before inflation adjustments. BCG's M&A Sentiment Index rose to 83 from 79 at the start of the year, still well below its long-term average of 100.

Africa Pushes for UN Security Council Seat, $300M Energy Fund Closes

New York – September 21, 2026 -- Africa's push for greater control over its resources and a stronger voice in global governance took center stage as business leaders, heads of state, and investors gathered for the fifth edition of Unstoppable Africa, held alongside the 81st UN General Assembly session at the Marriott Marquis in Times Square.

Guterres calls for Africa's permanent UN Security Council seat

UN Secretary-General António Guterres told delegates that Africa needs a permanent presence on the UN Security Council to contribute to global dialogue and action. He urged reforms so the continent's critical minerals generate local value and jobs rather than being exported raw.

MetaOptics Secures $10M From White Lion to Build US Metalens Fab

Singapore – September 21, 2026 -- MetaOptics Ltd (Catalist: 9MT) has secured an investment facility of up to US$10 million from White Lion Capital LLC, marking the Singapore-listed metalens maker's first institutional backer from the United States.

White Lion gains rights to up to 40 million new shares under warrant deed

Under the warrant deed, Los Angeles-based White Lion may exercise warrants at its discretion to raise up to US$10 million by issuing up to 40,000,000 new ordinary shares in MetaOptics. The deal arrives one year after MetaOptics listed on the Catalist board of the Singapore Exchange, and follows what the company describes as a period of design and evaluation requests from customers alongside shipped sampling units.

Telix to Acquire ITM in $1.65B Deal, Forming Radiopharma Giant

Melbourne – September 21, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has signed a strategic agreement to merge with ITM Isotope Technologies Munich SE in a deal valuing ITM at US$1.65 billion upfront on a cash-free, debt-free basis, with up to US$700 million in additional contingent consideration tied to regulatory and sales milestones.

Deal structures $1.25 billion in Telix stock alongside debt assumption

Under the agreement, ITM shareholders will receive approximately US$1.25 billion in the form of 105.8 million Telix shares priced at US$11.84 per share, released as Nasdaq-listed ADRs following escrow periods of up to 15 months. Telix will additionally assume US$302 million of ITM net debt at closing, with US$96 million allocated to management equity rollover and transaction expenses. Upon completion, existing Telix shareholders will hold roughly 76.3% of the combined company, with ITM shareholders holding approximately 23.7%.

01F Group Invests in Indonesia's DANA to Expand Digital Finance Access

Singapore – September 21, 2026 -- 01F Group has made an investment in DANA, Indonesia's leading digital e-wallet and financial services platform, through its growth-stage fintech private equity arm, 01Fintech. The deal deepens 01F Group's exposure to Southeast Asia's fintech sector as Indonesia's digital payments market is projected to approach USD 1 trillion by 2030.

DANA's platform reaches millions of users across Tier 2 to Tier 4 regions

DANA operates an integrated digital financial ecosystem serving consumers, merchants and financial institutions, with particular penetration among micro, small and medium enterprises (MSMEs) outside Indonesia's major metropolitan centers. Founded in 2018, the platform combines digital payments, QRIS transactions, money transfers and AI-powered financial tools.

Field Medical's PFA Catheter Hits 94.2% Vein Durability in 12-Month Trial

Atlanta and Carlsbad, Calif. – September 21, 2026 -- Field Medical, Inc. reported 12-month outcomes from its first-in-human Field PULSE trial showing 94.2% per-vein durability for pulmonary vein isolation using an optimized waveform, with results published in JACC: Clinical Electrophysiology and presented as a Late-Breaking Clinical Trial at HRX Live 2026.

Subsecond ablation cuts median procedure time to 13 minutes

The trial recorded a 13-minute median elapsed pulmonary vein isolation (PVI) ablation time, with a fastest case completed in 7.7 minutes. Field Medical's high-voltage focal pulsed field ablation (PFA) architecture, delivered through its FieldForce PFA System, applies energy in under 200 milliseconds per point, reducing the need for prolonged catheter stability during atrial procedures.

CleanSpark Unit Prices $2.276B Notes for Sandersville Data Center

Las Vegas – September 21, 2026 -- CleanSpark's wholly owned subsidiary CSDC Finance I, LLC has priced a $2.276 billion offering of 7.875% senior secured notes due 2031, sold at 98.500% of principal amount, to fund construction of the company's Sandersville Facility data center.

Notes target build-out costs, equity reimbursement and debt reserves

Net proceeds from the private offering will finance the remaining construction cost of the Sandersville Facility, reimburse CleanSpark for prior equity contributions made toward the project, and fund debt service reserves. The offering, conducted under Rule 144A and Regulation S to qualified institutional buyers and non-U.S. persons, is expected to close on September 21, 2026, subject to customary conditions.

Haymaker Acquisition Corp V Closes $287.5M SPAC IPO on NYSE

New York – September 21, 2026 -- Haymaker Acquisition Corp V raised $287.5 million in gross proceeds after closing its initial public offering of 28,750,000 units, including the full exercise of a 3,750,000-unit over-allotment option by underwriters.

Units Begin Trading on NYSE Under Ticker HYACU

The blank-check company priced its offering at $10.00 per unit, with shares beginning trading on the New York Stock Exchange on September 21, 2026. Each unit comprises one Class A ordinary share and one-third of a redeemable warrant, exercisable at $11.50 per share. Once separated, the Class A shares and warrants are expected to list under the symbols HYAC and HYACW.

Marel Power Wins $1.9M Michigan Grant for EV Power Stack Line

Plymouth, Mich. – September 20, 2026 -- Marel Power Solutions has secured $1.9 million through Michigan's Supplier Conversion Grant Program to fund a pilot production line for its power stack platform in Plymouth, Michigan.

Eleven suppliers split $21 million to retool for EV production

Marel is one of eleven Michigan automotive suppliers selected to share $21 million administered by the Michigan Department of Labor and Economic Opportunity (LEO). The program, backed by the U.S. Department of Energy's Domestic Automotive Manufacturing Conversion Grant initiative, targets domestic manufacturing capacity for vehicle components and helps established suppliers adapt to industry shifts toward electrification.

NAVER D2SF Backs ImpriMed's $10M Round for AI Cancer Diagnostics

Seoul – September 20, 2026 -- NAVER D2SF, the in-house corporate venture arm of NAVER, has joined a $10 million Series A2 bridge round for Silicon Valley-based precision medicine company ImpriMed, backing its push toward U.S. regulatory clearance and Asian market expansion.

ImpriMed targets FDA clearance and CLIA certification by Q1 2027 for its blood cancer platform

The company is preparing to commercialize diagnostic products for blood cancers and blood infection in the United States, having already established business partnerships with major U.S. hospitals. ImpriMed's xCellSense platform keeps patient-derived cancer cells viable outside the body for extended periods, allowing evaluation of drug sensitivity alongside genomic, immunophenotypic and clinical data. The company's AI models are trained on more than 3.5 million data points combining real-world data with functional cell analysis.